Get started
Author

Kaushal Patel

Observed name: Patel Kaushal
ORCID: 0000-0002-8404-3504
Observed ORCID: 0000-0002-8404-3504
OpenAlex ID: A5126509501
539 A randomized, double-blind, phase III trial to compare SB27 (a proposed biosimilar to pembrolizumab) to reference pembrolizumab in participants with metastatic non-squamous non-small cell lung cancer
2026 · Cengiz Karaçin, Jasuja Sandeep, et al. · Journal for ImmunoTherapy of Cancer
PDF
Impact of combined positive score in cetuximab plus chemotherapy in recurrent/metastatic head and neck cancer: A real-world study
2026 · Akhil Kapoor, Kaushal Patel, et al. · South Asian Journal of Cancer
PDF
Role of cetuximab in recurrent and/or metastatic head and neck cancer (R/M-HNC) in the era of immunotherapy: Consensus from India
2026 · M V Chandrakanth, Rajat Bajaj, et al. · South Asian Journal of Cancer
PDF
Real-World Outcomes for Maintenance Avelumab Treatment in Indian Patients with Locally Advanced/Metastatic Urothelial Cancer
2026 · Vineet Talwar, Kaushal Patel, et al. · Indian Journal of Medical and Paediatric Oncology
Impact of CPS on Indian Recurrent/Metastasis Oral Cavity Patients Treated with Cetuximab Plus Chemotherapy: A Real-World Study
2026 · Akhil Kapoor, Kaushal Patel, et al. · Indian Journal of Medical and Paediatric Oncology
Real-World Outcomes in Indian Patients with Recurrent or Metastatic Head and Neck Cancer Treated with Erbitux and Chemotherapy: Impact of CPS Score (RACE-Head Neck India)
2026 · Kaushal Patel, Akhil Kapoor, et al. · Indian Journal of Medical and Paediatric Oncology
Cetuximab in platinum-ineligible patients with locally advanced squamous cell carcinoma of the head and neck: Consensus from India
2025 · Agarwala Vivek, Aggarwal Shyam, et al. · Indian Journal of Cancer
Works count: 7
Citation count:
H-index:
I10-index:
Year
Topic
Type